{
  "id": 7182703,
  "title": "Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst",
  "url": "https://urgent.news/2026/09/13/novo-nordisk-may-be-poised-to-outpace-eli-lilly-with-this-key-catalyst",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-13T21:15:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/09/13/novo-nordisk-may-be-poised-to-outpace-eli-lilly-wi/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Novo Nordisk, the first company to develop a GLP-1 weight-loss drug, may soon surpass Eli Lilly in this emerging market. Initially designed for diabetics, the GLP-1 drug, under the brand names Wegovy and Ozempic, has gained popularity beyond its intended audience due to its weight-loss benefits. Novo Nordisk struggled to meet the high demand for their product, opening the door for Eli Lilly, which launched its own GLP-1 shot, Mounjaro and Zepbound, shortly after. Despite Eli Lilly's early lead in the weight-loss sector, the tides are now turning in Novo Nordisk's favor. Their drug appears to be as effective as Eli Lilly's, giving the former a potential advantage in the competitive market.",
  "summary": "Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst",
        "url": "https://urgent.news/2026/09/13/novo-nordisk-may-be-poised-to-outpace-eli-lilly-with-this-key-catalyst-7190561",
        "published": "2026-09-13T21:35:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}